Phase 1 Clinical Trial of Human Hookworm Vaccine Successfully Completed

Sabin's picture Submitted by Sabin on

WASHINGTON, D.C. — September 3, 2014 — The Sabin Vaccine Institute (Sabin) today announced that its product development partnership (Sabin PDP) successfully completed a Phase 1 clinical trial in Brazil of Na-GST-1/Alhydrogel®, a vaccine candidate for human hookworm, one of the most pervasive neglected tropical diseases (NTDs) affecting the world’s poor. The Sabin PDP is based at Sabin Vaccine Institute and Texas Children’s Hospital Center for Vaccine Development at Baylor College of Medicine in Houston, Texas.

Indonesia’s Competitiveness at risk from Neglected Diseases of Poverty

Sabin's picture Submitted by Sabin on

WASHINGTON, D.C. – February 27, 2014 – The control and elimination of neglected tropical diseases (NTDs) is one of the most cost-effective ways Indonesia can sustain economic growth and reduce inequality, said scientists today in an analysis published in PLOS Neglected Tropical Diseases. While Indonesia is poised to defeat NTDs by 2020, it has an opportunity to scale up national programs, integrate NTDs with other development efforts, strengthen coordination and enhance collaboration among key partners.